NasdaqGM:SIBN

Stock Analysis Report

Executive Summary

SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally.

Snowflake

Fundamentals

Excellent balance sheet with concerning outlook.


Similar Companies

Share Price & News

How has SI-BONE's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

NasdaqGM:SIBN

0.8%

US Medical Equipment

1.1%

US Market


1 Year Return

n/a

NasdaqGM:SIBN

9.6%

US Medical Equipment

2.1%

US Market

No trading data on SIBN.

No trading data on SIBN.


Share holder returns

SIBNIndustryMarket
7 Day0%0.8%1.1%
30 Day-1.7%0.2%3.7%
90 Day6.8%2.7%2.3%
1 Yearn/a10.5%9.6%4.4%2.1%
3 Yearn/a69.5%64.3%47.0%37.4%
5 Yearn/a132.5%105.9%61.6%43.8%

Price Volatility Vs. Market

How volatile is SI-BONE's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is SI-BONE undervalued based on future cash flows and its price relative to the stock market?

6.12x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for SI-BONE to establish if it is available at moderate discount.

Unable to calculate intrinsic value for SI-BONE to establish if it is available at substantial discount.


Price Based on Earnings

SI-BONE is loss making, we can't compare its value to the US Medical Equipment industry average.

SI-BONE is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for SI-BONE, we can't assess if its growth is good value.


Price Based on Value of Assets

SI-BONE is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is SI-BONE expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

35.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

SI-BONE's revenue is expected to grow by 18.7% yearly, however this is not considered high growth (20% yearly).

SI-BONE is not considered high growth as it is expected to be loss making for the next 1-3 years.

SI-BONE's revenue growth is expected to exceed the United States of America market average.

Unable to compare SI-BONE's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare SI-BONE's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if SI-BONE will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has SI-BONE performed over the past 5 years?

9.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

SI-BONE does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare SI-BONE's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare SI-BONE's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if SI-BONE has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if SI-BONE has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if SI-BONE improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is SI-BONE's financial position?


Financial Position Analysis

SI-BONE is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

SI-BONE's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

SI-BONE's level of debt (50.3%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (514.3% vs 50.3% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 3x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

SI-BONE has sufficient cash runway for more than 3 years based on current free cash flow.

SI-BONE has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 7.4% each year.


Next Steps

Dividend

What is SI-BONE's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate SI-BONE's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate SI-BONE's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as SI-BONE has not reported any payouts.

Unable to verify if SI-BONE's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as SI-BONE has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of SI-BONE's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of SI-BONE's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average management tenure


CEO

Jeff Dunn (63yo)

11.4yrs

Tenure

US$1,670,660

Compensation

Mr. Jeffrey W. Dunn serves as President and Chairman at SI-Bone Inc. Mr. Dunn is Chief Executive Officer of SI-Bone Inc. since April, 2008. Mr. Dunn served as President and Chief Executive Officer of Activ ...


CEO Compensation Analysis

Jeff's remuneration is about average for companies of similar size in United States of America.

Jeff's compensation has increased whilst company is loss making.


Management Age and Tenure

3.8yrs

Average Tenure

57yo

Average Age

The tenure for the SI-BONE management team is about average.


Board Age and Tenure

8.7yrs

Average Tenure

63yo

Average Age

The tenure for the SI-BONE board of directors is about average.


Insider Trading

SI-BONE individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$2,805,18127 Aug 19
Skyline Ventures
EntityCompany
Shares152,424
Max PriceUS$18.40
SellUS$958,47023 Aug 19
Skyline Ventures
EntityCompany
Shares47,576
Max PriceUS$20.17
SellUS$7,300,00014 Aug 19
Skyline Ventures
EntityCompany
Shares400,000
Max PriceUS$18.25
SellUS$4,34019 Jul 19
Scott Yerby
EntityIndividual
Role
Chief Technology Officer
Chief Technology Officer
Shares217
Max PriceUS$20.00
SellUS$28,94819 Jul 19
Jeffrey Dunn
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares1,436
Max PriceUS$20.16
SellUS$4,84019 Jul 19
Michael Pisetsky
EntityIndividual
Role
Chief Legal Officer
General Counsel
Shares242
Max PriceUS$20.00
SellUS$8,38019 Jul 19
Anthony Recupero
EntityIndividual
Role
Senior Key Executive
Chief Commercial Officer
Shares419
Max PriceUS$20.00
SellUS$9,70019 Jul 19
Laura Francis
EntityIndividual
Role
Chief Financial Officer
CFO & COO
Shares485
Max PriceUS$20.00
SellUS$3,06019 Jul 19
W. Reckling
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer & VP of Medical Affairs
Shares153
Max PriceUS$20.00
SellUS$12,31810 Jul 19
Scott Yerby
EntityIndividual
Role
Chief Technology Officer
Chief Technology Officer
Shares648
Max PriceUS$19.01
SellUS$3,58317 Apr 19
Scott Yerby
EntityIndividual
Role
Chief Technology Officer
Chief Technology Officer
Shares216
Max PriceUS$16.59
SellUS$7,06517 Apr 19
Anthony Recupero
EntityIndividual
Role
Senior Key Executive
Chief Commercial Officer
Shares427
Max PriceUS$16.55
SellUS$2,50517 Apr 19
W. Reckling
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer & VP of Medical Affairs
Shares151
Max PriceUS$16.59
SellUS$3,99817 Apr 19
Michael Pisetsky
EntityIndividual
Role
Chief Legal Officer
General Counsel
Shares241
Max PriceUS$16.59
BuyUS$3,000,00019 Oct 18
Arboretum Ventures LLC
EntityCompany
Shares200,000
Max PriceUS$15.00
BuyUS$3,000,00019 Oct 18
OrbiMed Advisors, L.L.C.
EntityCompany
Shares200,000
Max PriceUS$15.00
BuyUS$4,875,00019 Oct 18
Skyline Ventures
EntityCompany
Shares325,000
Max PriceUS$15.00

Ownership Breakdown


Management Team

  • Laura Francis (52yo)

    CFO & COO

    • Tenure: 4.3yrs
    • Compensation: US$734.33k
  • Scott Yerby (51yo)

    Chief Technology Officer

    • Tenure: 0yrs
  • Jeff Dunn (63yo)

    Chairman

    • Tenure: 11.4yrs
    • Compensation: US$1.67m
  • Tony Recupero (61yo)

    Chief Commercial Officer

    • Tenure: 3.2yrs
    • Compensation: US$489.03k
  • W. Reckling (57yo)

    Chief Medical Officer & VP of Medical Affairs

    • Tenure: 0yrs
  • Joe Powers (59yo)

    Vice President of Marketing

    • Tenure: 7.1yrs
  • Michael Pisetsky (41yo)

    General Counsel

    • Tenure: 3.1yrs
  • Jennifer Maggio

    VP & Corporate Controller

    • Tenure: 0.8yrs

Board Members

  • Ted Jr. Davis (48yo)

    Lead Independent Director

    • Tenure: 1.4yrs
    • Compensation: US$36.07k
  • Greg Hinckley (72yo)

    Director

    • Tenure: 8.7yrs
    • Compensation: US$37.45k
  • John Freund (65yo)

    Director

    • Tenure: 6.7yrs
    • Compensation: US$9.32k
  • Keith Valentine (51yo)

    Director

    • Tenure: 4.1yrs
    • Compensation: US$33.18k
  • Ralph Rashbaum

    Member of Medical Advisory Board

    • Tenure: 9.7yrs
  • Steve Garfin

    Member of Medical Advisory Board

    • Tenure: 8.8yrs
  • Frank Phillips

    Member of Medical Advisory Board

    • Tenure: 8.8yrs
  • Jeff Dunn (63yo)

    Chairman

    • Tenure: 11.4yrs
    • Compensation: US$1.67m
  • A. Shamie

    Member of Medical Advisory Board

    • Tenure: 8.8yrs
  • Jonathan Hyde

    Member of Surgeon Advisory Board

    • Tenure: 0yrs

Company Information

SI-BONE, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: SI-BONE, Inc.
  • Ticker: SIBN
  • Exchange: NasdaqGM
  • Founded: 2008
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$476.927m
  • Shares outstanding: 24.80m
  • Website: https://si-bone.com

Number of Employees


Location

  • SI-BONE, Inc.
  • 471 El Camino Real
  • Suite 101
  • Santa Clara
  • California
  • 95050
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SIBNNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDOct 2018
2K3MUN (Boerse Muenchen)YesCommon StockDEEUROct 2018
2K3DB (Deutsche Boerse AG)YesCommon StockDEEUROct 2018

Biography

SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/17 00:48
End of Day Share Price2019/09/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.